Skip to content

Greencare Capital - Grant of Options

Announcement provided by

MaxRets Ventures Plc · MAX

01/07/2021 11:00

Greencare Capital - Grant of Options
RNS Number : 8507D
Greencare Capital PLC
01 July 2021


Greencare Capital plc

("Greencare" or the "Company")


Grant of options


Greencare (AQSE: GRE), the investment company focused on investing in CBD and related wellness areas, announces that it has adopted a new unapproved Employees' Share Scheme (the "2021 Scheme") and made a grant of share options to a director. The 2021 Scheme supplements the Company's share option scheme adopted in May 2020 (the "2020 Scheme").


The vesting conditions and key terms of the 2021 Scheme are identical to the 2020 scheme, save for the exercise price and eligible participants. The 2021 Scheme and 2020 Scheme provide that options may be issued over a maximum of 10 per cent. of the Company's issued share capital in aggregate across both schemes, from time to time, and up to a maximum of 200 per cent. of an employee's annual salary.


The Company has granted options under the 2021 Scheme as follows:


Option holder


Number of      Options Granted

Exercise Price

Options Granted as Percentage of Issued Share Capital

Richard Tonthat








The exercise period for options granted under the 2021 Scheme and 2020 Scheme is three years from the date of grant. The vesting criteria for options granted under both schemes are as follows:


Amount Vesting

Time Condition

Performance Condition

50 per cent. ("Tranche One")

On the business day following the first financial year end following the date of grant


the NAV on the Tranche One Vesting Date not being less than the NAV on the Grant Date

50 per cent. ("Tranche two")

On the business day following the second financial year end following the date of grant

the NAV on the Tranche Two Vesting Date being a minimum of 10% higher than the NAV on the Grant Date


Vesting conditions may be varied or waived provided that any varied vesting condition shall be a fairer measure of performance, as judged at the time, and no more difficult to satisfy than the original vesting condition. Both schemes provide for good leaver provisions and other standard terms normally associated with such a scheme.


As a result of the grant of options detailed above, the Company has in issue options over 927,272 ordinary shares representing 6.27 per cent. of the Company's issued share capital. 


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"), as in force in the United Kingdom pursuant to the provisions of the European Union (Withdrawal) Act 2018.





Greencare Capital plc

Richard Tonthat, CEO


+44 (0)20 7933 8780

Cairn Financial Advisers LLP

AQSE Corporate Adviser

Jo Turner / James Lewis


+44 (0)20 7213 0885





Walbrook PR Limited

Paul Vann/Nicholas Johnson


+44 (0)20 7933 8780

+44 (0)7768 807631



Notification and public disclosure of transactions by persons discharging managerial responsibilities / person closely associated with them.



Details of the person discharging managerial responsibilities/person closely associated



Richard Tonthat


Reason for the notification



CEO, Director


Initial notification/Amendment

Initial Notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Greencare Capital plc





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument



Identification code



Nature of the transactions

Grant of Options


Price(s) and volume(s)




30.5 p




Aggregated information

-   Aggregated volume

-   Price



- 360,000


- 30.5p 




Date of the transactions

30 June 2021


Place of the transactions

AQSE Growth Market, UK


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

MAX announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal